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Background: Lipegfilgrastim is a novel glyco-pegylated granulocyte-colony stimulating factor in development for
neutropenia prophylaxis in cancer patients receiving chemotherapy. This phase III, double-blind, randomized,
active-controlled, noninferiority trial compared the efficacy and safety of lipegfilgrastim versus pegfilgrastim in
chemotherapy-naïve breast cancer patients receiving doxorubicin/docetaxel chemotherapy.
Methods: Patients with high-risk stage II, III, or IV breast cancer and an absolute neutrophil count ≥1.5 × 109 cells/L
were randomized to a single 6-mg subcutaneous injection of lipegfilgrastim (n = 101) or pegfilgrastim (n = 101) on
day 2 of each 21-day chemotherapy cycle (4 cycles maximum). The primary efficacy endpoint was the duration of
severe neutropenia during cycle 1.
Results: Cycle 1: The mean duration of severe neutropenia for the lipegfilgrastim and pegfilgrastim groups was 0.7
and 0.8 days, respectively (λ = −0.218 [95% confidence interval: –0.498%, 0.062%], p = 0.126), and no severe
neutropenia was observed in 56% and 49% of patients in the lipegfilgrastim and pegfilgrastim groups, respectively.
All cycles: In the efficacy population, febrile neutropenia occurred in three pegfilgrastim-treated patients (all in cycle 1)
and zero lipegfilgrastim-treated patients. Drug-related adverse events in the safety population were reported in 28%
and 26% of patients in the lipegfilgrastim and pegfilgrastim groups, respectively.
Conclusion: This study demonstrates that lipegfilgrastim 6 mg is as effective as pegfilgrastim in reducing neutropenia in
patients with breast cancer receiving myelosuppressive chemotherapy.
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The efficacy of myelosuppressive chemotherapy regimens
is often restricted by dose-limiting toxicities that can delay
subsequent treatment cycles. One of the most common
of these toxicities is a decrease in white blood cell counts,
particularly of the neutrophil granulocytic lineage, clinic-
ally defined as neutropenia. Although neutropenia per
se is asymptomatic, it is associated with many clinically
important complications, including increased risk for
opportunistic infection, febrile neutropenia (FN), sepsis,
and related morbidity and mortality.
The risk of initial infection and subsequent complica-
tions is inversely proportional to the absolute neutro-
phil count (ANC) and begins to increase when the ANC
is <1.5 × 109/L. Consequently, the National Cancer Insti-
tute has defined neutropenia as an ANC < 1.0 × 109/L [1];
this has also been designated as the minimum ANC re-
quired to initiate or continue chemotherapy cycles in
many therapeutic clinical trials [2-4]. Because fever is
often the only indication of an underlying infection in
the setting of severe/febrile neutropenia, immediate
hospitalization and administration of intravenous (i.v.)
antibiotics is required [5,6]. According to the American
Society of Clinical Oncology guidelines for antimicro-
bial prophylaxis and outpatient management of neutro-
penia in patients treated for cancer [7], patients with
febrile neutropenia should receive initial doses of empir-
ical antibacterial therapy within an hour of triage and
should either be monitored for at least 4 hours to deter-
mine suitability for either outpatient management or
admission to the hospital.
Recombinant granulocyte-colony stimulating factor
(G-CSF) products have emerged as effective therapies
for reducing the duration and incidence of chemotherapy-
induced neutropenia and FN by stimulating neutrophil
proliferation and differentiation in cancer patients [8,9].
Short-acting r-metHuG-CSFs (e.g., filgrastim) require
daily subcutaneous (s.c.) injections during each chemo-
therapy cycle. The attachment of a polyethylene glycol
(PEG) molecule (pegylation) to filgrastim (e.g., pegfilgrastim)
decreases plasma clearance and extends the drug’s half-life
in the body, allowing for less-frequent dosing [10,11].
Placebo-controlled clinical studies have shown significant
reductions in the incidence of FN in patients treated with
r-metHuG-CSF products [3,9]. Randomized, phase III,
comparative studies have demonstrated similar trends in pa-
tients treated with once-per-cycle fixed-dose pegfilgrastim
compared with once-daily filgrastim [2,12].
Lipegfilgrastim (XM22; Teva Pharmaceuticals Industries
LTD, PetachTikva Israel) is a once-per-cycle, glyco-
pegylated r-metHuG-CSF developed for the prevention
of chemotherapy-induced neutropenia. Clinical data
have shown lipegfilgrastim (6 mg) to be well tolerated in
healthy volunteers, with dose-dependent increases inbioavailability and ANC comparable to that seen in
pegfilgrastim (6 mg)-treated patients [13].
The primary objective of this study was to demon-
strate the noninferiority of lipegfilgrastim compared with
pegfilgrastim in patients with breast cancer during the
first cycle of chemotherapy with respect to duration of
severe neutropenia (DSN). Secondary evaluations of phar-
macokinetic (PK) properties associated with lipegfilgrastim




The study protocol was approved by the Ministry of
Health of Ukraine Central Ethics Committee and all
institutional review boards and local ethics committees
of the participating centers. All patients gave written
informed consent before any study-related procedures
were performed. Twenty-seven centers in Russia and
Ukraine enrolled and screened 218 breast cancer patients
(stage II, III, or IV) from May 2010 to December 2010.
Patients were eligible if they were at least 18 years of
age, had no prior chemotherapy treatments and were
eligible to receive four cycles of docetaxel and doxorubi-
cin for the treatment of high-risk stage II, III, or IV
breast cancer, had an Eastern Cooperative Oncology
Group (ECOG) performance status ≥2, and had an
ANC ≥1.5 × 109/L and a platelet count ≥100 × 109/L.
Patients were required to have adequate cardiac func-
tion (including left ventricular ejection fraction ≥50% as
assessed by echocardiography or equivalent method within
4 weeks prior to randomization), adequate hepatic func-
tion (i.e. alanine aminotransferase, aspartate aminotrans-
ferase both <2.5 × the upper limit of normal [ULN], alkaline
phosphatase and bilirubin <5 ×ULN). Patients were ex-
cluded if they had participated in a clinical trial 30 days
before randomization; had previous exposure to filgrastim,
pegfilgrastim, lenograstim, or other G-CSFs in clinical
development less than 6 months prior to randomization;
or had a known hypersensitivity to docetaxel or doxo-
rubicin, filgrastim, pegfilgrastim, or lenograstim. Ad-
ditional patient exclusion criteria included underlying
neuropathy of grade 2 or higher, treatment with lithium
at inclusion or during the study or antibiotics within
72 hours before chemotherapy, chronic use of oral
corticosteroids, prior bone marrow or stem cell trans-
plant, radiation therapy within 4 weeks prior to previous
5 years, and women who were pregnant or nursing.
Study design
This study was a phase III, multinational, multicenter,
randomized, double-blind, controlled study to evaluate
the safety and efficacy of a fixed dose of lipegfilgrastim
during the first cycle of chemotherapy versus pegfilgrastim
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bined myelosuppressive chemotherapy with doxorubicin
60 mg/m2 and docetaxel 75 mg/m2. Eligible patients were
randomized in a 1:1 ratio to receive a single fixed-dose s.c.
injection of either lipegfilgrastim 6 mg or pegfilgrastim
6 mg. Patients were assigned to treatment groups using a
permuted block randomization with a block size of two,
stratified by country. Chemotherapy was repeated every
3 weeks (unless a dose delay was necessary) for a max-
imum of four cycles.
Treatment procedures
On day 1 of each chemotherapy cycle, patients received
an i.v. bolus of doxorubicin (60 mg/m2) followed 1 hour
later by a 1-hour i.v. infusion of docetaxel (75 mg/m2).
Patients randomized to lipegfilgrastim or pegfilgrastim
received a single s.c. injection of 6 mg of active study
drug on day 2 of each cycle, approximately 24 hours
after chemotherapy. Both the study drug and the active
comparator drug were presented as identical prefilled
syringes, and administration was performed via s.c.
injection in the abdomen, upper arm, or thigh. Chemo-
therapy was repeated every 3 weeks for up to four cycles.
Full-dose chemotherapy was started on day 1 of each cycle
(day 22 of the previous cycle) only if a patient’s ANC
was ≥1.5 × 109/L and platelet count was ≥100 × 109/L. A
delay of up to 14 days in the initiation of the subsequent
cycle was allowed to provide time for these hematologic
parameters to be achieved.
Schedule of assessments
Blood samples were collected for ANC determination
within 24 hours of chemotherapy and then daily during
cycle 1 up to day 15 or until an ANC of ≥2.0 × 109/L
was reached. Blood samples on day 2 were taken before
study drug administration. ANC assessment for cycles 2,
3, and 4 was performed within 24 hours of chemother-
apy and on days 1 and 3, then daily on days 5–15 of
each cycle, until an ANC of ≥2.0 × 109/L was achieved.
Safety assessments (blood sampling for determination
of antibodies, physical examinations, vital signs) were
performed within 24 hours of chemotherapy in each
cycle (day 1) and at the end of the study. Blood samples
for PK assessments of lipegfilgrastim and pegfilgrastim
were collected in a subset of patients during cycles 1
and 4. Patients recorded their oral body temperature twice
daily until day 15 or until ANC reached ≥2.0 × 109/L, and
they were monitored for adverse events (AEs) and con-
comitant medication use throughout the study.
Endpoints
The primary efficacy endpoint was the duration in days of
severe neutropenia (grade 4, ANC <0.5 × 109/L; Common
Terminology Criteria for Adverse Events, version 3.0) inthe first cycle of chemotherapy of the per-protocol (PP)
study population. Incidence of FN in cycles 1–4 was a
secondary efficacy endpoint and was defined as severe
neutropenia in combination with one or more of the
following: oral body temperature >38.5°C for at least
1 hour; documentation of neutropenic sepsis; and docu-
mentation of serious or life-threatening infection. Other
secondary endpoints included duration of severe neu-
tropenia in cycles 2–4; incidence and duration of severe
and very severe neutropenia (ANC <0.1 × 109/L) in cycles
1–4; and the lowest ANC level reached (ANC nadir) in
each treatment cycle. Time to ANC nadir and to recovery
(defined as a return of ANC to ≥2.0 × 109/L) were also
assessed, as was the incidence of i.v. antibiotic administra-
tion, hospitalization, and overall quality of life.
Standard PK parameters (including area under the curve
[AUC], peak concentration [Cmax], and time to Cmax) were
calculated from serum concentrations of lipegfilgrastim
and pegfilgrastim measured at predefined time points in
cycles 1 and 4.
Safety was assessed by the incidence of AEs using pre-
ferred terms designated by the Medical Dictionary for
Regulatory Activities, changes in clinical chemistry, and
changes in hematology laboratory values over time.
Adverse events were classified as “bone-pain–related
symptoms” with a comprehensive definition including
the AE terms arthralgia, back pain, bone pain, neck
pain, myalgia, and other musculoskeletal symptoms.
Statistical analysis
The sample size of the study was based on a Poisson dis-
tribution of the target variable, DSN, as assessed by
Monte-Carlo simulations. Allowing for a difference in
DSN of 0.25 days in favor of pegfilgrastim in cycle 1, it
was determined that a sample size of at least 86 patients
per treatment group provided 90% power to reject the
null hypothesis if the true DSN of lipegfilgrastim was
within 1 day of that of pegfilgrastim.
Differences between treatment groups were analyzed
using the two-sided 95% confidence interval (CI), calcu-
lated using a Poisson regression with identity link, in-
cluding treatment, country, type of therapy (metastatic
versus adjuvant), and body weight as fixed factors and
with the last ANC value measured prior to the start of
study treatment (baseline ANC) as a covariate. In both
the intent-to-treat (ITT) and PP populations, lipegfilgrastim
was to be considered noninferior to pegfilgrastim for
the primary endpoint of DSN if, in cycle 1, the upper
limit of the two-sided 95% CI for the difference in DSN
was <1 day. The same variables were used in Poisson
and logistic regression model estimates for the secon-
dary efficacy endpoints.
For the calculation of PK parameters, concentration
values below the lower limit of quantification (defined as
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all other time points. For all time points used to calcu-
late PK metrics, the actual time after G-CSF was used; if
the actual time point was not available, the planned
sample times were used.
Analysis populations
The statistical analysis was based on separate, hierarch-
ically organized analysis populations. Demographic data
were analyzed for all of the following study populations:
included not randomized (INR), ITT, PP, and safety
populations. Efficacy data were analyzed for the ITT and
PP populations. The safety endpoints were analyzed for
the safety population. Demographic and baseline char-
acteristics were also presented for the PK population.
The INR population comprised all patients enrolled
but not randomized. The ITT population included all
patients who were randomized to one of the study treat-
ments at the baseline visit. The PP population was com-
prised of all patients in the ITT set for whom no major
protocol violations occurred. The safety population in-
cluded all randomized patients who received at least one
dose or partial dose of study medication. The ITT and
safety populations were identical, because all random-
ized patients were treated at least once with study medi-
cation. The PK sub-study population consisted of up to
20 patients per treatment group in selected centers. The
centers and patients were chosen on the basis of logistic
considerations.
The main population of interest for the efficacy mea-
sures was the PP population, because it is thought that
assessing the effects of the agents in patients with no
protocol violations may provide a more conservative
representation of observed drug effects than the ITT
population in clinical equivalence and noninferiority
trials. Patients with major protocol violations included
in ITT populations usually diminish possible treatment
effect differences, i.e., patients with protocol violations
usually act in favor of alternative hypotheses in statis-
tical noninferiority or equivalence tests [14]. The ITT
population statistics are included to affirm the results.
Chemotherapy dose adjustments
The dose of docetaxel was reduced from 75 mg/m2 to
60 mg/m2 for patients who experienced severe and/or
febrile neutropenia for more than 1 week, severe or
cumulative cutaneous reactions, or severe (grade 3/4)
peripheral neuropathy during therapy. The dose of doxo-
rubicin was reduced from 60 mg/m2 to 45 mg/m2 for pa-
tients who experienced severe and/or febrile neutropenia
for more than 1 week. The doses of both doxorubicin and
docetaxel were reduced by 25% for subsequent cycles if
patients had a platelet count of <2.0 × 1010/L at day 21
of a cycle.Prohibited concomitant treatments included radiother-
apy affecting the bone marrow, other investigational drugs
or G-CSFs, transfusions of granulocytes, other cytotoxic
treatment, and lithium. Prophylaxis with systemically (i.e.,
intramuscular, i.v., or oral) active antibiotics was not per-
mitted except for patients at high risk for infection as
assessed by the investigator. Treatment with antibiotics
was allowed for any increased temperature >38.5°C (oral);
if associated with severe neutropenia (ANC <0.5 × 109/L);
and for patients with a microbiologically, clinically, or
radiologically documented infection. Antipyretics were
only allowed if two consecutive temperature measure-
ments >38.5°C (oral) at least 1 hour apart from one an-
other were documented, or if fever occurred after
treatment with systemic antibiotics had been started.
Analgesics were to be avoided except in patients who
experienced pain associated with chemotherapy or study
drug. Corticosteroids (oral or i.v.) could be given if
deemed necessary (e.g. to prevent or immediately treat a
hypersensitivity reaction to a chemotherapeutic drug).
Herceptin was not allowed during chemotherapy treat-




Two hundred eighteen patients were screened for entry
into the study. As shown in Figure 1, 202 patients were
randomized (lipegfilgrastim: n = 101 and pegfilgrastim:
n = 101), received at least one dose of active treatment
and constituted both the efficacy ITT population and
safety population. A total of 193 (95.5%) patients initi-
ated all four cycles of chemotherapy. Seven patients with
major protocol violations were excluded from the PP
population in each treatment group (n = 94 per treatment
group). The PK substudy population was composed of 41
patients (lipegfilgrastim: n = 17 and pegfilgrastim: n = 24)
from the ITT population. The majority of patients in
both treatment groups received chemotherapy as sche-
duled, with the mean percentage of doxorubicin and
docetaxel actually administered reaching more than 98%
in each group in each cycle. Thirty one patients in the
lipegfilgrastim group and 36 patients in the pegfilgrastim
group received delayed chemotherapy treatment in cycles
2–4. There were no dose omissions or reductions in the
lipegfilgrastim group and eight in the pegfilgrastim group
in cycles 2–4.
Baseline characteristics
All patients in the ITT population were white,
chemotherapy-naïve women. Overall, 39%, 48%, and
14% of patients in the lipegfilgrastim group and 36%,
45%, and 20% in the pegfilgrastim group had stage II, III,
and IV breast cancer, respectively. Their mean ages ±
Figure 1 Disposition of patients. AE = adverse event, ANC = absolute neutrophil count.
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9.4 years for the lipegfilgrastim and pegfilgrastim groups,
respectively. The two groups were generally well bal-
anced for other demographic factors and disease status
at baseline (Table 1). Overall, 13 patients in the pegfilgrastim
group and 15 patients in the lipegfilgrastim group hadreceived previous radiotherapy. The majority of patients
were receiving chemotherapy as adjuvant therapy in the
lipegfilgrastim and pegfilgrastim groups (74.3% and
73.3%, respectively). Twenty-six percent of patients in
the lipegfilgrastim group and 27% of patients in the
pegfilgrastim group were receiving chemotherapy for
Table 1 Demographic and clinical characteristics









Mean age, years (± SD) 51.1 (9.4) 50.9 (9.3) 49.9 (10.1) 49.3 (10.0)
Age ≥65 years 7 (6.9) 6 (6.4) 7 (6.9) 6 (6.4)
Mean weight, kg (± SD) ≤ 73.2 (14.6) 73.6 (14.8) 73.9 (17.1) 73 (16.4)
Gender, n (%)
Female 101 (100.0) 94 (100.0) 101 (100.0) 94 (100.0)
Male 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Country, n (%)
Russia 63 (62.4) 61 (64.9) 63 (62.4) 60 (63.8)
Ukraine 38 (37.6) 33 (35.1) 38 (37.6) 34 (36.2)
Reason for chemotherapy, n (%)
Adjuvant therapy 74 (73.3) 70 (74.5) 75 (74.3) 71 (75.5)
Treatment for metastatic disease 27 (26.7) 24 (25.5) 26 (25.7) 23 (24.5)
Disease stage, n (%)
High-risk stage II 36 (35.6) 35 (37.2) 39 (38.6) 38 (40.4)
Stage III 45 (44.6) 44(46.8) 48 (47.5) 46 (48.9)
Stage IV 20 (19.8) 15 (16.0) 14 (13.9) 10 (10.6)
ECOG performance status,* n (%)
01 47 (46.5) 46 (48.9) 45 (44.6) 44 (46.8)
02 54 (53.5) 48 (51.1) 56 (55.4) 50 (53.2)
03 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Months since first diagnosis
Mean ± SD 6.1 ± 26.6 4.5 ± 20.3 5.3 ± 16.7 4.4 ± 15.6
Median (range) 1.0 (0–185.0) 1.0 (0–185.0) 2.0 (0–130.0) 1.0 (0–130.0)
Breast surgery, n (%)
Yes 41 (40.6) 57 (60.6) 51 (50.5) 45 (47.9)
No 60 (59.4) 37 (39.4) 50 (49.5) 49 (52.1)
Months since last surgery
N with surgery 60 57 50 45
Mean ± SD 9.1 ± 34.1 6.3 ± 25.8 6.7 ± 15.5 4.9 ± 12.3
Median (range) 1.0 (0–185.0) 1.0 (0–185) 1.0 (0–72.0) 1.0 (0–185)
Type of breast surgery,† n (%)
Breast-conserving surgery 7 (6.9) 6 (6.4) 4 (4.0) 2 (2.1)
Mastectomy 55 (54.5) 52 (55.3) 46 (45.5) 43 (45.7)
Axillary lymphadenectomy 46 (45.5) 44 (46.8) 44 (43.6) 40 (42.6)
*ECOG performance status: 0 = fully active, able to carry on all pre-disease performance without restriction; 1 = restricted in physically strenuous activity but
ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework, office work; 2 = ambulatory and capable of all self-care but unable to
carry out any work activities; up and about more than 50% of waking hours.
†Patients could be counted in multiple categories.
ECOG Eastern Cooperative Oncology Group, SD standard deviation.
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tics of the ITT population were similar to those of the
PP population.
Efficacy
Duration of severe neutropenia in cycle 1
In the PP population, the mean (±SD) duration of se-
vere neutropenia, the primary efficacy endpoint, wascomparable in both treatment groups: 0.8 ± 0.9 days in the
active control pegfilgrastim group and 0.7 ± 0.9 days
in the lipegfilgrastim group (Table 2). As a result, the
study met its primary endpoint and lipegfilgrastim
was noninferior to pegfilgrastim, with a 95% two-
sided CI of −0.498%, 0.062% days (p = 0.1260). Results
for the primary endpoint were similar in the ITT
population with a mean DSN of 0.7 ± 1.0 for the
Table 2 Duration of severe neutropenia in cycles 1–4 (per-protocol population)

















Mean ± SD 0.8 ± 0.9 0.7 ± 0.9 0.3 ± 0.6 0.1 ± 0.5 0.2 ± 0.4 0.1 ± 0.3 0.2 ± 0.5 0.2 ± 0.6
Median (range) 1 (0.0, 4.0) 0 (0.0, 4.0) 0 (0.0, 3.0) 0 (0.0, 3.0) 0 (0.0, 2.0) 0 (0.0, 2.0) 0 (0.0, 3.0) 0 (0.0, 3.0)
LS Mean (95% CI)* −0.218 (−0.498%, 0.062%) −0.123 (−0.282%, 0.036%) −0.029 (−0.145%, 0.087%) 0.008 (−0.147%, 0.163%)
p value† 0.1260 0.1287 0.6227 0.922
*Least-squares mean comparison of lipegfilgrastim versus pegfilgrastim by Poisson regression with treatment, country, type of therapy, and weight class as class
variables and absolute neutrophil count baseline as a covariable. Poisson regression with possible overdispersion.
†p value is based on null hypothesis of equality.
CI confidence interval, LS least-squares, SD standard deviation.
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group (p = 0.1841).
Incidence of febrile neutropenia in cycles 1 to 4
In the PP population, three patients (3.2%) who received
pegfilgrastim and none who received lipegfilgrastim de-
veloped FN (according to the strict definition) during
cycle 1. In the ITT population, three patients in the
pegfilgrastim group (same patients as in the PP popula-
tion) and one patient in the lipegfilgrastim group deve-
loped FN during the study. There was no statistically
significant observed difference in the incidence of FN
between the treatment groups where calculable. The
patient taking lipegfilgrastim who was assessed by an
investigator as having FN was excluded from the PP
population due to major protocol violations, and there
were insufficient data to confirm whether the patient
had or did not have FN according to the strict definition.
Duration of severe neutropenia in cycles 2 to 4
The DSN in each cycle was comparable between the treat-
ment and active control groups, with no observed statisti-
cally significant differences (Table 2). The mean DSN was
consistently shorter in cycles 2–4 than in cycle 1 in both
treatment groups. Of note, in each of cycles 2–4, more than
75% of the patients in each treatment group experienced
no severe neutropenia. The results in the ITT population
were consistent with those in the PP population.
Incidence of severe neutropenia in cycles 1 to 4
In the PP population, the incidence of severe neutro-
penia was not statistically significantly different between
the treatment and active control groups during cycles 1,
3, and 4. In cycle 2, 21.5% of patients in the pegfilgrastim
group and 8.5% of patients in the lipegfilgrastim group
had severe neutropenia (p = 0.0130, Table 3). Most cases
of severe neutropenia occurred in the first cycle, with
51.1% of patients in the pegfilgrastim cohort and 43.6%
of patients in the lipegfilgrastim cohort having severe
neutropenia during cycle 1 (p = 0.3409). The results of
the ITT population were consistent with those of the
PP population.Incidence and duration of very severe neutropenia in
cycles 1 to 4
The incidence of very severe neutropenia over all cycles
in the PP population was low in both groups (11.7% of
pegfilgrastim patients and 6.4% of lipegfilgrastim patients;
p = 0.2066). Similarly, the duration of very severe neu-
tropenia in each cycle was short in both treatment
groups, with no significant differences observed. The re-
sults in the ITT population were consistent with those
in the PP population.
Absolute neutrophil counts
The depth of ANC nadir for each cycle was defined as
the minimal ANC value for a patient in each respective
cycle. The depth of ANC nadir in both PP population
treatment groups was lowest in cycle 1, then increased
to ≥2.0 × 109/L in cycles 2–4. The depth of ANC nadir
in cycle 1 was comparable in both treatment groups
(p = 0.2539). In cycles 2, 3, and 4, the mean depth of
ANC nadir had higher absolute values for patients treated
with lipegfilgrastim compared with those treated with
pegfilgrastim (2.6 vs. 2.0, 2.5 vs. 2.0, and 2.7 vs. 2.3 × 109/L;
p = 0.0189, p = 0.0353, and p = 0.1122, respectively; Figure 2).
The median time of recovery to an ANC >2.0 × 109/L
in both PP population treatment groups was highest in
cycle 1 (7 days for lipegfilgrastim, 8 days for pegfilgrastim;
Figure 3). In cycles 1, 2, and 3, the time to ANC recovery
was shorter for lipegfilgrastim-treated patients than for
pegfilgrastim-treated patients (p < 0.05; Table 4). In cycle
4, the time to ANC recovery was comparable in both
treatment groups.
Safety
The safety profile of lipegfilgrastim was similar to that of
pegfilgrastim, with no patterns or trends indicative of in-
creased lipegfilgrastim toxicity. Treatment-emergent ad-
verse events (TEAEs) are summarized in Table 5. Most
TEAEs reported were attributable to complications of
myelosuppressive chemotherapy or the primary disease
(i.e., alopecia, nausea, asthenia, neutropenia) and oc-
curred in similar percentages of patients in each group
during the study. The overall frequencies of almost all
Table 3 Incidence of severe neutropenia in cycles 1–4 (per-protocol population)*





















n/N 48/94 41/94 20/93 8/94 11/91 8/93 11/91 11/90 55/94 47/94
(%) (51.1) (43.6) (21.5) (8.5) (12.1) (8.6) (12.1) (12.2) (58.5) (50.0)
OR (95% CI) 0.745 (0.405%, 1.369%) 0.291 (0.110%, 0.769%) 0.676 (0.249%, 1.835%) 0.997 (0.391%, 2.545%) 0.708 (0.383%, 1.309%)
p value† 0.3409 0.0130 0.4404 0.9958 0.2695
*Multiple mentions per patient are possible.
†Pegfilgrastim 6 mg vs. lipegfilgrastim 6 mg (p values are based on a null hypothesis of OR = 1).
























Figure 2 Absolute neutrophil count (ANC) nadir in cycles 1-4 (per-protocol population).
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highest frequencies in cycle 1 and lower frequencies in
cycles 2–4.
Serious TEAEs were reported in seven (6.9%) pegfilgrastim
patients and in three (3.0%) lipegfilgrastim patients. Three
cases of FN were reported in the pegfilgrastim group and
one was reported in the lipegfilgrastim group of the
safety population. Severe TEAEs were reported in 34.7%
of pegfilgrastim patients and 25.7% of lipegfilgrastim
patients. One patient treated with a single dose of
lipegfilgrastim died during this study. Upon autopsy,
enterocolitis was proven as the cause of death and was
determined not to be related to study medication by
the investigator.
Adverse events of special interest
“Bone-pain–related symptoms” according to the com-



























Figure 3 Median absolute neutrophil count (ANC) by day in chemothAE in 17 (16.8%) pegfilgrastim patients and in 24 (23.8%)
lipegfilgrastim patients, but the difference was not statisti-
cally significant. Rates of component AEs such as bone pain
(9.9% of pegfilgrastim patients and 13.9% of lipegfilgrastim
patients), myalgia (5.9%, 8.9%), and arthralgia (2.0%, 5.0%)
were also comparable between arms. None of the AEs
related to bone-pain–related symptoms led to the dis-
continuation of study participation, and none were ser-
ious. All were mild or moderate in severity as expected
under G-CSF treatment and were either well managed
using standard analgesics or required no additional
treatment.
Incidence of hospitalization and antibiotic treatment
Two patients in the pegfilgrastim group and one patient
in the lipegfilgrastim group were hospitalized due to FN
or infection. All three patients were hospitalized during
cycle 1 (one pegfilgrastim patient for 6 days and the7 8 9 10 11 12 13 14 15
otherapy cycle
Lipegfilgrastim 6 mg
erapy cycle 1 (per-protocol population).
Table 4 Time to ANC recovery in cycles 1–4 (per protocol population)

















Mean ± SD 7.4 ± 3.6 5.9 ± 3.4 5.3 ± 4.6 3.6 ± 4.1 5.1 ± 4.3 3.9 ± 4.8 4.3 ± 4.7 3.3 ± 4.1
Median (range) 8 (0–21.0) 7 (0–12.0) 7 (0–18.0) 0 (0–15.0) 7 (0–13.0) 0 (0–21.0) 6 (0–21.0) 0 (0–13.0)
LS mean −1.589 −1.661 −1.344 −0.802
(95% CI)* (−2.615%, –0.563%) (−2.885%, –0.436%) (−2.579%, −0.108%) (−2.098%, 0.493%)
p value† 0.0026 0.0082 0.0332 0.2234
*Least-squares mean, 95% CI, and p value are for the Poisson regression analysis lipegfilgrastim – pegfilgrastim.
†p value is based on null hypothesis of equality.
CI confidence interval, LS least-squares, SD standard deviation.
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http://www.biomedcentral.com/1471-2407/13/386other for 5 days; the lipegfilgrastim patient for 1 day)
and received antibiotics; the lipegfilgrastim patient also re-
ceived antipyretics. One other patient in the pegfilgrastim
group required antibiotics due to FN in cycle 1 but was
not hospitalized. The lipegfilgrastim patient who was hos-
pitalized due to FN was not included in the PP population
because of protocol violations.Pharmacokinetic subanalysis
The PK of 6 mg lipegfilgrastim and of 6 mg pegfilgrastim
after s.c. administration were similar in many respects, but
differed in the AUC. In cycle 1, descriptively, the geo-
metric means of AUC0-last and AUC0-∞ were higher for
lipegfilgrastim compared with pegfilgrastim (14,157 ng/
mL/h vs. 10,532 ng/mL/h and 14,184 ng/mL/h vs.
10,554 ng/mL/h, respectively). In cycle 4, the geometric
means of AUC0-last and AUC0-∞ were higher for
pegfilgrastim (4812 ng/mL/h and 4839 ng/mL/h, re-
spectively) compared with lipegfilgrastim (2975 ng/mL/h
and 3588 ng/mL/h, respectively) but in both cases were
lower than in cycle 1.Table 5 Frequencies of treatment-emergent adverse
events (TEAEs)* (safety population)




n (%) n (%)
Any TEAE 99 (98.0) 100 (99.0)
Drug-related TEAE = TEADR 26 (25.7) 28 (27.7)
Serious TEAE 7 (6.9) 3 (3.0)
Serious TEADR 1 (1.0) 1 (1.0)
Severe TEAE 35 (34.7) 26 (25.7)
Severe TEADR 2 (2.0) 1 (1.0)
Discontinued due to TEAE 2 (2.0) 3 (3.0)
Discontinued due to
TEADR
1 (1.0) 0 (0)
Death 0 (0) 1 (1.0)
*Patients could be counted in multiple categories.
TEAE treatment-emergent adverse event; TEADR treatment-emergent adverse
drug reaction.Discussion
The results of this study demonstrate the noninferiority
of lipegfilgrastim versus the active control pegfilgrastim
in patients with breast cancer who are receiving myelosup-
pressive chemotherapy. The incidence and duration of se-
vere neutropenia in patients who received lipegfilgrastim
was similar to or lower than that of patients who received
pegfilgrastim. The results of this study substantiate the
findings of a previous lipegfilgrastim dose-finding study
in breast cancer patients, which reported a mean DSN
of 0.8 days in the 6-mg lipegfilgrastim group and
0.9 days in the 6-mg pegfilgrastim group in cycle 1 [15].
The results for the analyses of all secondary efficacy
endpoints were consistent with those of the primary
endpoint, with lipegfilgrastim demonstrating comparable
efficacy to the active comparator pegfilgrastim. Where
differences between the groups were observed, the dif-
ferences favored greater antineutropenic activity for
lipegfilgrastim compared with pegfilgrastim.
The DSN observed in either treatment group was
considerably shorter than values reported in previous
clinical studies of breast cancer patients who received
similar myelosuppressive chemotherapy but were not
treated with a G-CSF [4]. delGiglio et al. [4] reported a
mean DSN of 3.8 days in cycle 1 in patients with breast
cancer not receiving G-CSF support. A prolonged mean
DSN of 5.7 days was also reported in a study of patients
with non–small-cell lung cancer [16]. Moreover, his-
torical data from breast cancer patients treated with
pegfilgrastim reported a considerably longer mean DSN
in cycle 1 of 1.8 days, compared with 0.7 days in
lipegfilgrastim-treated patients in the current study [2].
There was a relatively low occurrence of FN in the
present study. This is in contrast to a previous clinical
study in breast cancer patients that applied the same
chemotherapy regimen and had very similar inclusion
and exclusion criteria in which a higher incidence of FN
in pegfilgrastim-treated patients (9% [7 of 80 patients])
was reported [2]. This discrepancy was most likely the re-
sult of a less restrictive definition of FN (38.2°C measured
once instead of 38.5°C measured twice with a 1-hour
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http://www.biomedcentral.com/1471-2407/13/386interval). The reductions in the rate of FN are in line with
the results of a meta-analysis of 15 randomized, placebo-
controlled trials in which rates of FN were significantly
lower in G-CSF–treated groups than controls (22.4% vs.
39.5%, respectively [relative risk = 0.54; 95% CI: 0.43%,
0.67%; p < 0.0001]) [17].
Lipegfilgrastim had a favorable safety profile consistent
with that of a G-CSF [10]. Frequencies of AEs were ge-
nerally comparable between the treatment groups. The
most commonly experienced AEs were alopecia, nausea,
asthenia, neutropenia, bone pain, erythema, leukopenia,
and diarrhea. The only AEs that differed in frequency
by ≥5% between the treatment groups were alopecia,
nausea, neutropenia, and vomiting. However, these dif-
ferences were not considered to be clinically relevant,
as all of the aforementioned AEs are known to be asso-
ciated with the chemotherapy regimen or the under-
lying disease. G-CSF bone pain–related symptoms were
comparable between treatment arms [11]. These side
effects were mild or moderate in severity, well managed
using standard analgesics, and did not lead to early dis-
continuation of study treatment.
The PK of lipegfilgrastim 6 mg and pegfilgrastim 6 mg
after s.c. administration were generally similar with one
key difference: lipegfilgrastim had a higher AUC0-last and
AUC0-∞ compared with pegfilgrastim in cycle 1. Given
that both AUC parameters were almost 50% higher for
lipegfilgrastim compared with pegfilgrastim in cycle 1,
the activity of a 6-mg lipegfilgrastim dose would be
expected to be greater than that of pegfilgrastim 6 mg.
This is consistent with the efficacy and safety results
observed in this study, with a trend toward a somewhat
higher effect observed for lipegfilgrastim in terms of
anti-neutropenic activity.Conclusions
The current study demonstrates that a single fixed-dose
injection of lipegfilgrastim 6 mg was noninferior to the
active control pegfilgrastim in patients with breast can-
cer receiving myelosuppressive chemotherapy. Overall,
lipegfilgrastim has a safety profile that is consistent with
a G-CSF and acceptable for the intended patient popula-
tion. Results of this study are compelling because the
introduction of new treatments may help improve the
cost efficacy of managing cancer patients receiving
chemotherapy.
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